- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04973605
Vaiheen 1b/2 tutkimus BGB-11417:stä monoterapiassa ja useissa yhdistelmissä deksametasonin ja karfiltsomibin kanssa multippeli myeloomassa
Vaiheen 1b/2 annoksen suurennus- ja kohortin laajennustutkimus BGB-11417:n turvallisuuden ja tehokkuuden määrittämiseksi monoterapiana yhdistettynä deksametasonin ja karfiltsomibi/deksametasonin kanssa potilailla, joilla on uusiutunut/refraktorinen multippeli myelooma ja myelooma ja 14t (11;14)
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).
The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: BeOne Medicines
- Puhelinnumero: 1.877.828.5568
- Sähköposti: clinicaltrials@beonemed.com
Opiskelupaikat
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, ACT 2605
- Rekrytointi
- Canberra Hospital
-
-
New South Wales
-
Kingswood, New South Wales, Australia, NSW 2747
- Rekrytointi
- Nepean Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, VIC 3168
- Rekrytointi
- Monash Health
-
Fitzroy, Victoria, Australia, VIC 3065
- Rekrytointi
- St Vincents Hospital Melbourne
-
Melbourne, Victoria, Australia, VIC 3004
- Rekrytointi
- The Alfred Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, WA 6000
- Rekrytointi
- Royal Perth Hospital
-
-
-
-
-
Brasília, Brasilia, 70200-730
- Rekrytointi
- Hospital Sirio Libanes Brasilia
-
Brasília, Brasilia, 70390140
- Rekrytointi
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre, Brasilia, 90110-270
- Rekrytointi
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador, Brasilia, 41253-190
- Rekrytointi
- Hospital Sao Rafael (Rede Dor)
-
São Paulo, Brasilia, 05652-900
- Rekrytointi
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasilia, 01401-004
- Rekrytointi
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
São Paulo, Brasilia, 01308-050
- Rekrytointi
- Hospital Sirio Libanes
-
-
-
-
-
Barcelona, Espanja, 08036
- Aktiivinen, ei rekrytointi
- Hospital Clinic de Barcelona
-
-
-
-
Seoul Teugbyeolsi
-
GangnamGu, Seoul Teugbyeolsi, Etelä -Korea, 06351
- Rekrytointi
- Samsung Medical Center
-
SeochoGu, Seoul Teugbyeolsi, Etelä -Korea, 06591
- Rekrytointi
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu, Seoul Teugbyeolsi, Etelä -Korea, 03722
- Rekrytointi
- Severance Hospital Yonsei University Health System
-
Seoul, Seoul Teugbyeolsi, Etelä -Korea, 03080
- Rekrytointi
- Seoul National University Hospital
-
SongpaGu, Seoul Teugbyeolsi, Etelä -Korea, 05505
- Rekrytointi
- Asan Medical Center
-
-
-
-
-
Ancona, Italia, 60020
- Rekrytointi
- Azienda Ospedaliera Universitaria Delle Marche
-
Bari, Italia, 70124
- Rekrytointi
- Azienda Ospedaliera Policlinico Di Bari
-
Bologna, Italia, 40138
- Rekrytointi
- Policlinico Sorsola Malpighi, Aou Di Bologna
-
Meldola, Italia, 47014
- Rekrytointi
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
-
Milan, Italia, 20141
- Rekrytointi
- Istituto Europeo Di Oncologia
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Rekrytointi
- Cross Cancer Institute
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- Rekrytointi
- British Columbia Cancer Agency the Vancouver Centre
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrytointi
- Princess Margaret Cancer Centre
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 100044
- Rekrytointi
- Peking University Peoples Hospital
-
Beijing, Beijing Municipality, Kiina, 100000
- Rekrytointi
- Peking University Third Hospital
-
Beijing, Beijing Municipality, Kiina, 100020
- Rekrytointi
- Beijing Chao Yang Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kiina, 400030
- Rekrytointi
- Chongqing Cancer Hospital
-
-
Fujian
-
Fuzhou, Fujian, Kiina, 350001
- Valmis
- Fujian Medical University Union Hospital
-
Xiamen, Fujian, Kiina, 361003
- Valmis
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, Kiina, 510060
- Rekrytointi
- Sun Yat Sen University Cancer Center
-
-
Hebei
-
Shijiazhuang, Hebei, Kiina, 050000
- Valmis
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, Kiina, 450000
- Rekrytointi
- Henan Cancer Hospital
-
Zhengzhou, Henan, Kiina, 450052
- Aktiivinen, ei rekrytointi
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, Kiina, 430022
- Rekrytointi
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, Kiina, 410013
- Valmis
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Kiina, 210029
- Rekrytointi
- Jiangsu Province Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Kiina, 332000
- Rekrytointi
- The First Affiliated Hospital of Nanchang University Branch Xianghu
-
-
Liaoning
-
Shenyang, Liaoning, Kiina, 110001
- Rekrytointi
- The First Hospital of China Medical University
-
-
Shandong
-
Qingdao, Shandong, Kiina, 266000
- Rekrytointi
- Qingdao Municipal Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kiina, 200032
- Rekrytointi
- Affiliated Zhongshan Hospital of Fudan University
-
Shanghai, Shanghai Municipality, Kiina, 200434
- Valmis
- Shanghai Fourth Peoples Hospital Affiliated to Tongji University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kiina, 301617
- Rekrytointi
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
-
Tianjin, Tianjin Municipality, Kiina, 300052
- Valmis
- Tianjin Medical University General Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kiina, 310003
- Rekrytointi
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
-
-
-
-
Alexandroupoli, Kreikka, 68100
- Rekrytointi
- University Hospital of Alexandroupolis
-
Athens, Kreikka, 115 28
- Rekrytointi
- General Hospital of Athens Alexandra
-
-
-
-
-
Poitiers, Ranska, 86000
- Valmis
- Chu de Poitiers Site de La Mileterie
-
-
-
-
-
Aachen, Saksa, 52074
- Rekrytointi
- Universitaetsklinikum Aachen
-
Dresden, Saksa, 01307
- Rekrytointi
- Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
-
Hamburg, Saksa, 20251
- Rekrytointi
- Universitatsklinikum Hamburg Eppendorf
-
Würzburg, Saksa, 97080
- Rekrytointi
- Universitatsklinikum Wurzburg
-
-
-
-
-
Singapore, Singapore, 119074
- Rekrytointi
- National University Hospital Singapore
-
-
-
-
-
Headington, Yhdistynyt kuningaskunta, OX3 7LE
- Rekrytointi
- Oxford University Hospitals Nhs Trust Churchill Hospital
-
London, Yhdistynyt kuningaskunta, NW1 2PG
- Rekrytointi
- University College Hospital
-
Sutton, Yhdistynyt kuningaskunta, SM2 5PT
- Rekrytointi
- Royal Marsden Nhs Foundation Royal Marsden Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Yhdysvallat, 35294-0004
- Rekrytointi
- University of Alabama At Birmingham Hospital
-
-
California
-
Duarte, California, Yhdysvallat, 91010-3012
- Rekrytointi
- City of Hope National Medical Center
-
Irvine, California, Yhdysvallat, 92618-2377
- Rekrytointi
- City of Hope Irvine Lennar
-
-
Florida
-
Miami, Florida, Yhdysvallat, 33136-2107
- Rekrytointi
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322-1013
- Rekrytointi
- Emory University Winship Cancer Center
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60637-1443
- Rekrytointi
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02114
- Valmis
- Massachusetts General Hospital
-
-
Missouri
-
St Louis, Missouri, Yhdysvallat, 63110-1010
- Rekrytointi
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Yhdysvallat, 07601-1915
- Rekrytointi
- Hackensack University Medical Center
-
-
New York
-
New York, New York, Yhdysvallat, 10065-6800
- Rekrytointi
- Memorial Sloan Kettering Cancer Center Mskcc
-
-
Ohio
-
Columbus, Ohio, Yhdysvallat, 43210-1240
- Rekrytointi
- The James Cancer Hospital and Solove Research Institute At Ohio State University
-
-
Utah
-
Salt Lake City, Utah, Yhdysvallat, 84112-5550
- Rekrytointi
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98195
- Rekrytointi
- University of Washington
-
-
Wisconsin
-
Madison, Wisconsin, Yhdysvallat, 53792-0001
- Rekrytointi
- University of Wisconsin Carbone Cancer Center
-
Milwaukee, Wisconsin, Yhdysvallat, 53226-3522
- Rekrytointi
- Medical College of Wisconsin
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
-
A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)
-
Measurable disease defined as:
i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio
-
Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.
i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.
ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.
- In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
- Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
- Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD
-
Positivity for t(11;14) translocation must be confirmed by validated fluorescence in situ hybridization (FISH) testing assay in a pre-defined laboratory
a. fresh bone marrow aspirate sample must be collected at screening and sent to central laboratory for t(11;14) FISH testing.
-
Adequate organ function defined as:
- Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted)
- Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions
- Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ≤ 2.0 x ULN N (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)
Exclusion Criteria:
-
Participant has any of the following conditions:
- Non secretory MM (Serum free light chains < 10 mg/dL)
- Solitary plasmacytoma
- Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or > 2.0 x 109/L circulating plasma cells by standard differential)
- Waldenström macroglobulinemia (WM)
- Amyloidosis.
- Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
- Chronic respiratory disease that requires continuous oxygen
-
Significant cardiovascular disease, including but not limited to:
- Myocardial infarction ≤ 6 months before screening
- Ejection fraction ≤ 50%
- Unstable angina≤ 3 months before screening
- New York Heart Association Class III or IV congestive heart failure
- History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- Heart rate-corrected QT interval > 480 milliseconds based on Fridericia's formula
- History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
- Uncontrolled hypertension at screening, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg by ≥ 2 consecutive measurements. Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
-
Known infection with human immunodeficiency virus (HIV)
-
Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection as follows:
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Participants with presence of HBcAb, but absence of HBsAg, are eligible if HBV DNA is undetectable (limitation of sensitivity < 20 IU/mL) ,), and if they are willing to undergo monthly monitoring for HBV reactivation.
- Presence of HCV antibody. Participants with presence of HCV antibody are eligible if HCV RNA is undetectable (limitation of sensitivity < 15 IU/mL).
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Part 1 Dose Escalation
Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide. |
Administered orally daily
Muut nimet:
Once weekly either orally or intravenously Administered intravenously weekly Administered subcutaneously weekly Administered orally daily |
|
Kokeellinen: Part 2 Cohort Expansion
There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab |
Administered orally daily
Muut nimet:
Once weekly either orally or intravenously Administered intravenously weekly |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Osa 1 ja 2: Yhden tai useamman hoidon aiheuttavan haittatapahtuman (TEAES), vakavien haittavaikutusten (SAE), haittavaikutusten, erityisesti kiinnostavien haittatapahtumien (ASES) johtavien osallistujien lukumäärä.
Aikaikkuna: Jopa 30 päivää viimeisen annoksen jälkeen tutkimuslääkettä
|
Jopa 30 päivää viimeisen annoksen jälkeen tutkimuslääkettä
|
|
|
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Aikaikkuna: Up to 28 days
|
DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol. |
Up to 28 days
|
|
Part 2: Overall response rate (ORR) as Assessed by Investigator
Aikaikkuna: Approximately 4 years
|
Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria |
Approximately 4 years
|
|
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
Aikaikkuna: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
|
Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR) |
Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
|
|
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
Aikaikkuna: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])
|
defined as the percentage of participants with a documented CR or sCR |
Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Osa 1: Alue plasman konsentraatio-ajankäyrän aika 0 viimeiseen mitattavissa olevaan konsentraatioon (auclasti) yhden Sonrotoclax-annoksen jälkeen
Aikaikkuna: Sykli 1 (jokainen sykli on enintään 28 päivää)
|
Sykli 1 (jokainen sykli on enintään 28 päivää)
|
|
|
Osa 1: Suurin havaittu plasmapitoisuus (CMAX) yhden annoksen Sonrotoclaxin jälkeen
Aikaikkuna: Sykli 1 (jokainen sykli on enintään 28 päivää)
|
Sykli 1 (jokainen sykli on enintään 28 päivää)
|
|
|
Osa 1: Aika saavuttaa CMAX (TMAX) yhden annoksen Sonrotoclaxin jälkeen
Aikaikkuna: Sykli 1 (jokainen sykli on enintään 28 päivää)
|
Sykli 1 (jokainen sykli on enintään 28 päivää)
|
|
|
Osa 1: Vakaan tilan: AUC Last, SS
Aikaikkuna: Sykli 2 (jokainen sykli on enintään 28 päivää)
|
Sykli 2 (jokainen sykli on enintään 28 päivää)
|
|
|
Osa 1: Vakaan tilan: Cmax, SS
Aikaikkuna: Sykli 2 (jokainen sykli on enintään 28 päivää)
|
Sykli 2 (jokainen sykli on enintään 28 päivää)
|
|
|
Osa 1: Vakaan tilan: Plasmapitoisuus (Ctrough) SS
Aikaikkuna: Sykli 2 (jokainen sykli on enintään 28 päivää)
|
Sykli 2 (jokainen sykli on enintään 28 päivää)
|
|
|
Osa 1: Vakaantila: Aika saavuttaa Cmax (Tmax, SS)
Aikaikkuna: Sykli 2 (jokainen sykli on enintään 28 päivää)
|
Sykli 2 (jokainen sykli on enintään 28 päivää)
|
|
|
Part 2: Time to response (TTR) as Assessed by Investigator
Aikaikkuna: Approximately 4 years
|
TTR is defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to first documentation of response of Partial Response (PR) or better |
Approximately 4 years
|
|
Part 2: Duration of response (DOR) as Assessed by Investigator
Aikaikkuna: Approximately 4 years
|
DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to any cause, whichever occurs first. DOR will be analyzed only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method. |
Approximately 4 years
|
|
Part 2: Progression-free survival (PFS) as Assessed by Investigator
Aikaikkuna: Approximately 4 years
|
PFS is defined as time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts) to the first documentation of disease progression or death, whichever occurs first |
Approximately 4 years
|
|
Part 2: Overall survival (OS) as Assessed by Investigator
Aikaikkuna: Approximately 4 years
|
OS defined as the time from start of treatment (for nonrandomized cohorts) or date of randomization (for randomized cohorts to the date of death due to any cause |
Approximately 4 years
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Verisuonisairaudet
- Sydän-ja verisuonitaudit
- Neoplasmat
- Immuunijärjestelmän sairaudet
- Neoplasmat histologisen tyypin mukaan
- Hematologiset sairaudet
- Lymfoproliferatiiviset häiriöt
- Immunoproliferatiiviset häiriöt
- Neoplasmat, plasmasolut
- Hemostaattiset häiriöt
- Paraproteinemiat
- Veren proteiinien häiriöt
- Hemorragiset häiriöt
- Hemic- ja imusuutteet
- Multippeli myelooma
- Polisykliset yhdisteet
- Raskaat
- Raskaat
- Steroidit
- Sulatettu rengasyhdisteet
- Fluoratut steroidit
- Raskaat
- Deksametasoni
- karfiltsomibi
- pomidomidi
- daratumumabi
Muut tutkimustunnusnumerot
- BGB-11417-105
- 2021-003614-39 (EudraCT-numero)
- U1111-1277-5444 (Muu tunniste: UTN Number)
- 2023-507751-30-00 (Ctis)
- CTR20231932 (Muu tunniste: ChinaDrugTrials)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD-jaon aikakehys
See plan description
IPD-jaon käyttöoikeuskriteerit
See plan description
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .